mRNA Therapy Reducing Immune Reactogenicity via Immunomodulating Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA therapy using lipid nanoparticles (LNPs) faces limitations due to immune reactogenicity, which restricts tolerable doses and repeated dosing, primarily characterized by increased blood cell counts, neutrophil expansion, decreased lymphocyte and monocyte counts, and elevated interleukin-6 (IL-6) levels.
Innovation Solution
Incorporating an immunomodulating agent that reduces neutrophil expansion, lymphocyte trafficking, monocyte trafficking, and blocks or reduces IL-6 function/expression, often in combination with mRNA constructs encoded in lipid nanoparticles, to mitigate immune reactogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If mRNA therapy is administered at higher doses or repeated dosing is performed, then therapeutic efficacy is improved, but immune reactogenicity increases causing adverse immune reactions
Solution Approach 1:
The patent introduces an immunomodulating agent as an intermediary substance that mediates between the mRNA therapy and the immune system. This agent specifically modulates immune responses to reduce reactogenicity while preserving therapeutic efficacy, allowing higher doses and repeated dosing without excessive immune reactions
Solution Approach 2:
The patent changes the immunological parameters of the system by introducing agents that alter immune cell behavior (neutrophil expansion, lymphocyte trafficking, monocyte trafficking) and cytokine levels (IL-6). These parameter changes enable higher mRNA doses to be administered without triggering excessive immune responses
2Quantity of substance
If immunomodulating agents are used to reduce immune reactogenicity, then tolerable doses and repeated dosing potential are improved, but treatment complexity increases
Solution Approach 1:
The immunomodulating agent serves multiple functions simultaneously: it reduces neutrophil expansion, modulates lymphocyte trafficking, affects monocyte trafficking, and regulates IL-6 levels. This multi-functionality allows a single agent to address multiple aspects of immune reactogenicity without proportionally increasing treatment complexity
Data Source
AI summary
The present disclosure provides compositions and methods for mRNA therapy with reduced immune reactogenicity.